Rhythm Pharmaceuticals, Inc.
General ticker "RYTM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.6B (TTM average)
Rhythm Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 54.9%.
Estimated limits based on current volatility of 2.5%: low 101.89$, high 107.22$
Factors to consider:
- Total employees count: 283 (+25.2%) as of 2024
- US accounted for 73.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Clinical trial delays, Regulatory and compliance, Economic downturns and volatility, Cybersecurity threats
- Current price 64.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [30.25$, 64.22$]
- 2025-12-31 to 2026-12-31 estimated range: [24.92$, 54.24$]
Financial Metrics affecting the RYTM estimates:
- Negative: with PPE of -12.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.35 <= 0.33
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.61 <= 0.79
- Negative: negative Industry operating cash flow (median)
Short-term RYTM quotes
Long-term RYTM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $23.64MM | $77.43MM | $130.13MM |
| Operating Expenses | $202.79MM | $261.79MM | $395.63MM |
| Operating Income | $-179.16MM | $-184.36MM | $-265.50MM |
| Non-Operating Income | $-1.96MM | $0.24MM | $5.25MM |
| Interest Expense | $5.20MM | $13.89MM | $20.60MM |
| R&D Expense | $108.63MM | $134.95MM | $237.96MM |
| Income(Loss) | $-181.12MM | $-184.11MM | $-260.26MM |
| Taxes | $0.00MM | $0.56MM | $0.35MM |
| Profit(Loss)* | $-181.12MM | $-184.68MM | $-260.60MM |
| Stockholders Equity | $264.26MM | $169.76MM | $21.73MM |
| Inventory | $2.92MM | $8.62MM | $18.74MM |
| Assets | $382.48MM | $332.75MM | $392.27MM |
| Operating Cash Flow | $-173.43MM | $-136.16MM | $-113.88MM |
| Capital expenditure | $4.28MM | $0.05MM | $0.00MM |
| Investing Cash Flow | $28.03MM | $-5.67MM | $-48.17MM |
| Financing Cash Flow | $213.83MM | $74.37MM | $191.24MM |
| Earnings Per Share** | $-3.47 | $-3.20 | $-4.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.